Fate therapeutics presents 6-month follow-up data on first patient treated in phase 1 autoimmunity study with fludarabine-free conditioning and ft819 off-the-shelf, 1xx car t-cell product candidate at acr convergence

27-year-old african american-asian woman with active lupus nephritis achieved doris clinical remission; patient remains on-study, in clinical remission, and free of all immunosuppressive therapies
CAR Ratings Summary
CAR Quant Ranking